ArticleTranslational cancer research2019
Expression levels and the prognostic value of long non-coding RNA PVT1 in serum of Han and Uygur gastric cancer patients in Xinjiang, China.
Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Calcium overload via PVT1 reprograms neutrophil fate and constrains gastric cancer progression.Journal of translational medicine · 2025Article
- Decoding the regulatory landscape of lncRNAs as potential diagnostic and prognostic biomarkers for gastric and colorectal cancers.Clinical and experimental medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe expression level of a long non-coding RNA (lncRNA), plasmacytoma variant translocation 1 (PVT1), was studied in serum of Han and Uygur gastric cancer (GC) patients and normal persons in Xinjiang, China, and the prognostic value of PVT1 was analyzed.
methodsWe collected serum samples from 87 GC patients (51 Han and 36 Uygur), and 95 normal persons (55 Han and 40 Uygur). Total RNA was extracted from the serum and used for real-time polymerase chain reaction (PCR) to detect the level of PVT1.The relationships between PVT1 and clinicopathological features were analyzed using the Spearman's relative analysis, rank sum test, and χ
resultsThe serum expression level of PVT1 was higher than that of the normal group in both Han and Uygur GC patients (P<0.05). PVT1 expression in Uygur GC serum was higher than that of Han patients (P<0.05). The high level of serum PVT1 correlated with lymph node metastasis in both Han and Uygur GC patients (P<0.05). Compared with Han GC patients, the Uygur people were more likely to develop distant metastasis (P<0.05). Uygur patients were more often diagnosed at stage III or IV (P<0.05). In addition, serum PVT1 showed a significant correlation with CA19-9 in Han GC patients (P<0.05).
conclusionsIncreased serum PVT1 level may indicate an increased tendency for lymphatic metastasis, especially in Uygur GC patients. When combined with CA19-9, the PVT1 expression level may be a better diagnostic marker in Han GC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.